Evidence map›Paper›PMID 38078653›Full record

ArticleDevelopment (Cambridge, England)2023

Programming human cell fate: overcoming challenges and unlocking potential through technological breakthroughs.

Hsiu-Chuan Lin, Aly Makhlouf, Camila Vazquez Echegaray, Dorota Zawada, Filipa Simões

Open access · hybridAbstract read
In one paragraph

Article in Development (Cambridge, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 5 countries.

Hsiu-Chuan LinDepartment of Biosystems Science and Engineering, ETH Zürich, 4057 Basel, Switzerland.ORCID 0000-0001-9587-6483
Aly MakhloufMRC Laboratory of Molecular Biology, University of Cambridge, Cambridge CB2 0QH, UK.ORCID 0000-0003-4025-0576
Camila Vazquez EchegarayMolecular Medicine and Gene Therapy, Lund Stem Cell Centre, Wallenberg Centre for Molecular Medicine, Lund University, 221 84 Lund, Sweden.ORCID 0000-0001-8849-6853
Dorota ZawadaFirst Department of Medicine, Cardiology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, 81675 Munich, Germany.ORCID 0000-0003-1127-7980
Filipa SimõesDepartment of Physiology, Anatomy and Genetics, Institute of Developmental and Regenerative Medicine, University of Oxford, Oxford OX3 7TY, UK.ORCID 0000-0003-2956-0311
ETH Zurich · CHLund University · SEMRC Laboratory of Molecular Biology · GBTUM Klinikum · DEUniversity of Oxford · GB

Funding

British Heart Foundation FS/IBSRF/21/25088European Research Council 788381Medical Research Council MC_UP_1201/24
6 · The paper itself

Abstract

In recent years, there have been notable advancements in the ability to programme human cell identity, enabling us to design and manipulate cell function in a Petri dish. However, current protocols for generating target cell types often lack efficiency and precision, resulting in engineered cells that do not fully replicate the desired identity or functional output. This applies to different methods of cell programming, which face similar challenges that hinder progress and delay the achievement of a more favourable outcome. However, recent technological and analytical breakthroughs have provided us with unprecedented opportunities to advance the way we programme cell fate. The Company of Biologists' 2023 workshop on 'Novel Technologies for Programming Human Cell Fate' brought together experts in human cell fate engineering and experts in single-cell genomics, manipulation and characterisation of cells on a single (sub)cellular level. Here, we summarise the main points that emerged during the workshop's themed discussions. Furthermore, we provide specific examples highlighting the current state of the field as well as its trajectory, offering insights into the potential outcomes resulting from the application of these breakthrough technologies in precisely engineering the identity and function of clinically valuable human cells.

Indexed as

Cellular ReprogrammingCell DifferentiationHumansCell programmingGenomic engineeringHuman cell fateReprogrammingSynthetic biology

Identifiers

PMID38078653
PMCPMC10753584
OpenAlexW4389572704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.